EndoTAG-1 (paclitaxel liposomal) - SynCore Biotechnology
Company Presentation (MediGene) - Sep 4, 2012 - "PFS rate (16 wks) in combination therapy group 59.1%; mOS (41 wks) in combination therapy group up to 13.0 months, in subgroup (ECOG 0/1, first line) up to 17.8 months" 
P2 data Breast Cancer
http://www.larvolonline.com/tlg/ccdb/MedigeneCompanyPresentationAug012012.pdf
 
Sep 4, 2012
 
(IR7)
 
d569c6ff-17cd-421e-8b06-0c98fc327bef.jpg